The essentials
FDA approves Merck's Lipfendra oral cholesterol pill, reducing LDL by 55-60% at $10.50 daily.
The FDA has approved Merck's enlicitide pill, marketed as Lipfendra, for cholesterol reduction. Clinical trials demonstrated the medication reduces LDL cholesterol by 55-60 percent, positioning it as a significant advance in cholesterol management.
Lipfendra is priced at $10.50 per day, substantially lower than injectable alternatives currently available. The approval reflects a market need, as approximately 47 million Americans take cholesterol medications. Merck benefited from an FDA National Priority Voucher, which accelerated the drug review process and brought the treatment to patients faster.
Other ways to read this story.
Alternative framings generated by SigNews. These are not independent sources or attributed quotations.
Lipfendra delivers significant LDL reduction in pill form
The clinical data shows 55-60% LDL reduction, a substantial therapeutic outcome. Delivering this efficacy in an oral tablet rather than injection represents a practical advance for patients who prefer pill-based treatments. This approval expands treatment options for the 47 million Americans managing cholesterol levels.
New oral option enters crowded cholesterol treatment landscape
At $10.50 daily, Lipfendra positions itself as a cost-effective alternative to injectable therapies. The expedited FDA review through the National Priority Voucher shortened the path to market. The approval adds a new oral choice in a therapeutic area serving millions of patients seeking accessible cholesterol management.